Edesa Biotech, Inc.
EDSAAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Nov 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 29, 2023 |
| HC Wainwright & Co. | maintain | Buy | Nov 22, 2023 |
| Brookline Capital | maintain | Buy | Oct 12, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 24, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 23, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | Dec 20, 2021 |
Earnings History
Next report: Dec 11, 2026 · EPS est. $-0.58| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.60 | $-0.43 | — | — |
| May 14, 2026 | $-0.49 | $-0.24 | — | — |
| Feb 13, 2026 | $-0.28 | $-0.28 | — | — |
| Dec 12, 2025 | $-0.32 | $-0.27 | — | — |
| Aug 8, 2025 | $-0.25 | $-0.26 | — | — |
| May 14, 2025 | $-0.30 | $-0.30 | — | — |
| Feb 14, 2025 | $-0.48 | $-0.31 | — | — |
| Dec 13, 2024 | $-0.29 | $-0.54 | — | — |
News
TORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that management will participate in Guggenheim's 3rd Annual Healthcare Innovation Conference, including a fireside chat and one-on-one investor meetings.
TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment to the United States. Patient recruitment is underway in Canada and the fi…
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded…
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has commenced an underwritten public offering of its common shares (or pre-funded warrants to purchase common shares in lieu thereof) and accompanying common share warrants to purchase common shares. In addition, Edesa expects to grant the unde…
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2026 and provided an update on its business.